ArticleJOR spine2026
Platelet-Rich Fibrin Induces New Bone Formation to Promote Extreme Lateral Interbody Fusion of Spine in Rabbits.
Article in JOR spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Achieving rapid bone fusion is critical for preventing complications in Extreme Lateral Interbody Fusion (XLIF), yet harvesting sufficient autologous bone presents surgical limitations. Platelet-rich fibrin (PRF), an autologous biomaterial rich in osteogenic growth factors, offers potential as a bone graft enhancer. This study evaluated the efficacy of PRF combined with allogeneic bone in promoting interbody fusion using an XLIF-simulated rabbit model. Methods: In vitro, bone marrow mesenchymal stem cells were cultured with PRF, allogeneic bone, or PRF/allogeneic bone composites. Assessments included biocompatibility (CCK-8, Calcein-AM/PI), cell adhesion (phalloidin/DAPI), and osteogenic differentiation (alkaline phosphatase activity/staining, Alizarin Red S). PRF, allogeneic bone, and their composite (PRF/allogeneic bone) were evaluated in a rabbit XLIF model. Autologous iliac crest bone served as a positive control, while empty cages provided negative controls. Endpoints included radiographic (micro-CT), mechanical (biomechanical testing), histological (H&E, methylene blue-acid fuchsin, TRAP), and biochemical (ELISA) evaluation at postoperative 2, 4, 8, and 12 weeks. Results: In vitro experiments demonstrated that PRF/allogeneic bone composites exhibited noncytotoxic properties and osteogenic-promoting effects when combined with titanium alloy cages. In vivo, fusion progressed temporally across all groups, with the PRF/allogeneic bone composite yielding 12-week fusion rates by manual palpation and micro-CT equivalent to autograft. Biomechanical strength and bone mineral density of PRF/allogeneic bone matched autograft, exceeding allogeneic bone. Histology demonstrated accelerated fusion kinetics: early angiogenesis (2 weeks), fibrocartilage formation (4 weeks), and complete trabecular bridging by 12 weeks. ELISA confirmed earlier BMP-2/VEGF peaks (2-4 weeks) versus allogeneic bone. Conclusions: These results indicated that the combination of PRF and allogeneic bone successfully induced intervertebral bone formation in the rabbit XLIF model. PRF can serve as a physiological natural fusion material, inducing osteogenesis and achieving spinal fusion. Its osteopromotive effects, cost-effectiveness, and autologous origin support its potential as a superior graft alternative for XLIF procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.